A Cost-Effectiveness Analysis Of An Adenocarcinoma Risk Prediction Multi-Biomarker Assay For Patients With Barrett's Esophagus.

Jing HaoRebecca Critchley-ThorneDavid L DiehlSusan R Snyder

Published in: ClinicoEconomics and outcomes research : CEOR (2019)

Given the model assumptions, the new Assay would be cost-effective after 5 years and improves patient outcomes due to improvement in the effectiveness of surveillance and treatment protocols resulting in fewer patients progressing to HGD and EAC and fewer EAC-related deaths.

Keyphrases

end stage renal disease
high throughput
ejection fraction
newly diagnosed
randomized controlled trial
chronic kidney disease
public health
squamous cell carcinoma
systematic review
peritoneal dialysis
patient reported outcomes